NASDAQ:TBPH - Theravance Biopharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $27.75 +0.76 (+2.82 %) (As of 12/12/2018 08:53 AM ET)Previous Close$26.99Today's Range$27.12 - $28.0752-Week Range$21.27 - $35.48Volume152,497 shsAverage Volume234,387 shsMarket Capitalization$1.48 billionP/E Ratio-5.09Dividend YieldN/ABeta2.11 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria. Its product candidates include TD-1792 that has completed Phase III clinical trials for the treatment of skin and soft tissues infections; Revefenacin (TD-4208), a long-acting muscarinic antagonist, which has completed Phase III clinical studies for chronic obstructive pulmonary disease (COPD); and Velusetrag (TD-5108), an oral and investigational medicine that has completed Phase IIb studies for gastrointestinal motility disorders. The company's product candidates also comprise TD-8954, a selective 5-HT4 receptor agonist for treating gastrointestinal motility disorders; TD-1473, a pan-Janus kinase inhibitor, which has completed Phase Ib clinical study for ulcerative colitis; TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor that has completed Phase II study for neurogenic orthostatic hypotension; and TD-0714 and TD-1439 Neprilysin inhibitors, which have completed Phase I clinical studies for heart failure and chronic kidney disease. In addition, it focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium bromide, and vilanterol for the treatment of COPD and asthma; the inhaled bifunctional muscarinic antagonist-beta2 agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. The company was incorporated in 2013 and is based in George Town, the Cayman Islands. Receive TBPH News and Ratings via Email Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TBPH Previous SymbolNASDAQ:TBPHV CUSIPN/A Webwww.theravance.com Phone650-808-6000 Debt Debt-to-Equity Ratio6.52 Current Ratio3.26 Quick Ratio3.08 Price-To-Earnings Trailing P/E Ratio-5.09 Forward P/E Ratio-6.62 P/E GrowthN/A Sales & Book Value Annual Sales$15.39 million Price / Sales99.91 Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book13.03 Profitability EPS (Most Recent Fiscal Year)($5.45) Net Income$-285,400,000.00 Net Margins-513.41% Return on Equity-505.90% Return on Assets-58.89% Miscellaneous Employees340 Outstanding Shares55,410,000Market Cap$1.48 billion OptionableOptionable Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions What is Theravance Biopharma's stock symbol? Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH." How were Theravance Biopharma's earnings last quarter? Theravance Biopharma Inc (NASDAQ:TBPH) posted its quarterly earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.08. The biopharmaceutical company had revenue of $12.84 million for the quarter, compared to analyst estimates of $10.55 million. Theravance Biopharma had a negative return on equity of 505.90% and a negative net margin of 513.41%. View Theravance Biopharma's Earnings History. When is Theravance Biopharma's next earnings date? Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Theravance Biopharma. What price target have analysts set for TBPH? 4 brokerages have issued 1-year target prices for Theravance Biopharma's shares. Their forecasts range from $38.00 to $55.00. On average, they expect Theravance Biopharma's share price to reach $47.00 in the next year. This suggests a possible upside of 69.4% from the stock's current price. View Analyst Price Targets for Theravance Biopharma. What is the consensus analysts' recommendation for Theravance Biopharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma. What are Wall Street analysts saying about Theravance Biopharma stock? Here are some recent quotes from research analysts about Theravance Biopharma stock: 1. According to Zacks Investment Research, "Theravance Biopharma has a single marketed product in its portfolio called Vibativ. We are upbeat about Theravance’s efforts to expand Vibativ’s label, which if approved for additional indications, would be commercially significant. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as in the past. Shares of the company have outperformed the industry in the past six months. Meanwhile, the company’s regulatory filing for Yupelri (revefenacin) for COPD was accepted by the FDA in January 2018 with a response expected by the year end." (11/16/2018) 2. Cantor Fitzgerald analysts commented, "We rate TBPH 12-month price target of $55. We believe the Street is underestimating the peak sales potential of its four key programs (JAK Inhibitor, NEP Inhibitors, TD-9855, Revefenacin), all of which have data expected this year. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $55. Our DCF analysis arrives at a 12-month share price of $60." (11/9/2018) 3. Needham & Company LLC analysts commented, "Theravance provided a 2Q18 corporate update today and announced top-line results from the Phase 2 trial of Hypotension (NOH). An impact on both blood pressure and symptoms is apparent and mgmt announced plans to start a Phase 3 trial around YE18. Separately, Phase 2 trial of Colitis (UC) has also been completed. As a reminder, 80mg data had previously been disclosed. Mgmt noted that a dose-response across 20mg-80mg-270mg is evident and that full data will be presented later this yr. Initiation of larger and longer-term trials in UC and Crohns Disease are planned for 2H18. We continue to expect Yupelri (revefenacin) FDA approval in COPD by 11/13/18 PDUFA date. Reiterate BUY. Pipeline is diverse, but Theravance is making noteworthy progress w/ several programs." (8/1/2018) Has Theravance Biopharma been receiving favorable news coverage? News stories about TBPH stock have been trending positive on Wednesday, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Theravance Biopharma earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. Who are some of Theravance Biopharma's key competitors? Some companies that are related to Theravance Biopharma include Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH), Emergent Biosolutions (EBS), Horizon Pharma (HZNP) and Array Biopharma (ARRY). Who are Theravance Biopharma's key executives? Theravance Biopharma's management team includes the folowing people: Mr. Rick E. Winningham, Chairman & CEO (Age 58)Ms. Reneé D. Galá, Sr. VP, CFO & Treasurer (Age 46)Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 58)Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)Mr. Frank Pasqualone, Sr. VP & Global Head of Acute Care Bus. (Age 62) Who are Theravance Biopharma's major shareholders? Theravance Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.96%), Vanguard Group Inc. (6.63%), Candriam Luxembourg S.C.A. (0.46%), TIAA CREF Investment Management LLC (0.29%), Teachers Advisors LLC (0.25%) and Alps Advisors Inc. (0.18%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Frank Pasqualone, Henrietta Fore, Philip D Worboys, Renee D Gala and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma. Which major investors are selling Theravance Biopharma stock? TBPH stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG and Rhumbline Advisers. Company insiders that have sold Theravance Biopharma company stock in the last year include Bradford J Shafer, Philip D Worboys and Renee D Gala. View Insider Buying and Selling for Theravance Biopharma. Which major investors are buying Theravance Biopharma stock? TBPH stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Vanguard Group Inc., BlackRock Inc., Ibex Investors LLC, TIAA CREF Investment Management LLC, Teachers Advisors LLC, Engineers Gate Manager LP and Alps Advisors Inc.. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Frank Pasqualone, Henrietta Fore and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma. How do I buy shares of Theravance Biopharma? Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Theravance Biopharma's stock price today? One share of TBPH stock can currently be purchased for approximately $27.75. How big of a company is Theravance Biopharma? Theravance Biopharma has a market capitalization of $1.48 billion and generates $15.39 million in revenue each year. The biopharmaceutical company earns $-285,400,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Theravance Biopharma employs 340 workers across the globe. What is Theravance Biopharma's official website? The official website for Theravance Biopharma is http://www.theravance.com. How can I contact Theravance Biopharma? Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected] MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 196 (Vote Outperform)Underperform Votes: 232 (Vote Underperform)Total Votes: 428MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?